Y-mAbs to Announce Third 2021 Financial and Operating Results on November 4, 2021

On October 28, 2021 Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (Nasdaq: YMAB) reported that it will report its financial results for the quarter ended September 30, 2021 on Thursday, November 4, 2021, after the close of the U.S. financial markets (Press release, Y-mAbs Therapeutics, OCT 28, 2021, View Source [SID1234592193]). The announcement will be followed by a conference call and webcast with the investment community on Friday, November 5, 2021, at 9 a.m. ET. Participating on the call from Y-mAbs will be Thomas Gad, founder, Chairman and President; Dr. Claus Moller, Chief Executive Officer; and Bo Kruse, Chief Financial Officer.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!


Lexicon Pharmaceuticals to Host Third Quarter 2021 Financial Results Conference Call and Webcast on November 3, 2021

On October 28, 2021 Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), reported that it will release its third quarter 2021 financial results on Wednesday, November 3, 2021 after the markets close (Press release, Lexicon Pharmaceuticals, OCT 28, 2021, View Source [SID1234592186]). Management will conduct a conference call and live webcast at 5:00 p.m. ET (4:00 p.m. CT) that day to discuss the financial results and to provide a business update.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The dial-in replay will be available for 14 days following the call. An audio webcast will be available online at www.lexpharma.com/events, with a webcast replay accessible for 14 days after the call.

HUYABIO Announces FDA Clearance to Initiate a Phase 1 Trial of SHP2 Inhibitor in Patients with KRAS and EGFR Mutated Tumors

On October 28, 2021 HUYABIO International (HUYABIO), the leader in accelerating global development of China’s pharmaceutical innovations, reported the FDA clearance of HBI-2376 as an Investigational New Drug, or IND, for a Phase 1 study (Press release, HUYA Bioscience, OCT 28, 2021, View Source [SID1234592181]). The authorization to proceed enables the first testing in patients for whom this novel SHP2 inhibitor might show clinical benefit.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are pleased to see that our partner HUYABIO is initiating clinical testing of our SHP2 inhibitor in the US, which will complement Genhouse’s clinical development program in China. We are expecting IND approval in November in China. We believe our SHP2 inhibitor will bring clinical benefit to cancer patients worldwide," said Dr. Kuifeng Wang, CEO of Genhouse.

The HUYABIO-sponsored Phase 1 trial is an open-label dose escalation study using the Company’s SHP2 inhibitor to measure the safety and tolerability in patients with solid tumors harboring KRAS or EGFR mutations. Anti-tumor effects of the monotherapy, determined according to RECIST 1.1, included among the secondary endpoints of the study. Up to 6 sites in the US will be involved in the study that will enroll 42 patients.

Dr. Mireille Gillings, CEO & Executive Chair of HUYABIO said, "We are excited to have FDA clearance to begin clinical testing of HBI-2376 because of the enormous potential of the drug against a number of different tumors. This represents another important milestone for HUYABIO in building a strong oncology pipeline with products that address significant unmet need and provide potential benefit to patients afflicted with debilitating malignancies."

About HBI-2376

HBI-2376 is an oral small molecule inhibitor of SHP2 targeting multiple tumor types whose cellular growth is dependent on the activity of receptor tyrosine kinases in the mitogen-activated protein kinase, or MAPK, pathway. Extensive biochemical characterization has shown that HBI-2376 is a highly potent and selective inhibitor of SHP2 phosphatase with the potential for activity as a single agent or in combination with various other targeted agents, including checkpoint inhibitors.

Aligos Therapeutics to Announce Third Quarter 2021 Results November 4, 2021

On October 28, 2021 Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, reported that it will report the company’s third quarter 2021 financial results on Thursday, November 4, 2021 after the close of U.S. financial markets (Press release, Aligos Therapeutics, OCT 28, 2021, View Source [SID1234592165]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!


Susan G. Komen Maximizes Breast Cancer Donor Dollars by Going Fully Remote with RingCentral Cloud Communications

On October 28, 2021 RingCentral, Inc. (NYSE: RNG), a leading provider of global enterprise cloud communications, video meetings, collaboration, and contact center solutions, reported that Susan G Komen, the world’s leading breast cancer organization, has turned to RingCentral MVP (Message Video Phone) to drive business communications across its entire operations (Press release, Susan G Komen, OCT 28, 2021, View Source [SID1234592161]). Since implementing RingCentral, Susan G. Komen has shifted its workforce to be fully remote, enabling employees to work from anywhere. The company has also ceased outsourcing its call center by deploying RingCentral Contact Center, bringing their helpline in-house. With these combined savings, the non profit organization is able to become more operationally efficient and dedicate more funds in support of its mission programming, such as advocacy, research, patient care, and support.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Susan G. Komen has invested more than $3 billion in groundbreaking research, community health outreach, advocacy, and programs in more than 60 countries since its founding in 1982, which is funded by donations from organizations and individuals—many of them pledged over the phone. For that reason, the nonprofit organization needed a more reliable communications solution as its previous on-premise communications system caused frequent outages, which meant a loss of potential donor funding. Additionally, the lack of mobility from their previous phone system prevented them from being able to implement a fully remote workforce.

"RingCentral gives us so much mobility and freedom. If I’m on a call or a RingCentral Video meeting on my laptop, and I need to run an errand, I can just switch the call to my mobile phone and head out. It’s fantastic for keeping us all productive and connected without tying us to our desks—or tying us anywhere for that matter," said Carlos Soto, hosted system administrator for Susan G. Komen. "The best part of being able to go 100% remote is that we can better invest that money into furthering our fight against breast cancer. I’ve never seen a more win-win situation for our organization."

Upon rolling out RingCentral Contact Center as its new customer support solution, support teams are improving many aspects of Komen’s operations and are now able to offer an elevated level of service. For example, Komen now has the capability to escalate a call with RingCentral’s three-way functionality to dial in a supervisor or emergency services if a patient exhibits the potential for self-harm. Having this solution in place for higher intensity calls brings their team confidence and peace of mind. To further assist the Helpline Specialists’ daily operations, the organization is using RingCentral’s out of the box integration with Salesforce. The integration enables its agents to easily take notes during a call and not have to re-enter the data. Those notes go straight into that caller’s Salesforce profile, where the next agent can see them, offering continuity and a more personalized level of service for future calls.

"It is so humbling and inspiring to see organizations like Susan G. Komen change the world for the better using our solutions," said Faiza Hughell, chief customer officer for RingCentral. "Empowering teams to keep doing the great work they do is our ultimate goal. Yes, the integrations we’ve built into our tools make things more efficient for support agents. However, they’ve let us know that the best part about capabilities like these is that for a person going through something as challenging as breast cancer, not having to retell their story each time makes for a much more comfortable experience."